Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 8/20 | 0.39 |
| ▸ | HTR2C | P28335 | 8/20 | 0.39 |
| ▸ | HTR2B | P41595 | 8/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4462976 | 1.00 | KDM4E (0.39) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4462035 | 0.90 | HTR2A (0.50) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4462038 | 0.90 | HTR2A (0.50) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4467617 | 0.90 | HTR2A (0.50) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4475013 | 0.87 | PDE4B (0.39) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4475010 | 0.87 | PDE4B (0.39) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4468755 | 0.86 | HTR2A (0.54) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4469612 | 0.86 | HTR2A (0.54) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4472913 | 0.86 | HTR2A (0.54) | KDM4EHTR2AHTR2CHTR2BMAPT | |
| SCHEMBL4465351 | 0.86 | HTR2A (0.54) | KDM4EHTR2AHTR2CHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572805-B2 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1778225-A2 | PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS | Bristol-Myers Squibb Company (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006019886-A2 | PYRROLO(OXO)ISOQUINOLINES AS 5HT LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014777-A1 | Pyrrolo(oxo)isoquinolines as 5HT ligands | HTR2B, OPRD1, HTR1B | KDM4E 2789/4885HTR2A 31/4885HTR2C 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.